One To Watch
Reunion Neuroscience
Company Overview
A clinical-stage biotechnology company developing luvesilocin, the only 4-OH-DiPT prodrug in clinical development, for postpartum depression, adjustment disorder, and generalized anxiety disorder. Reunion Neuroscience is pushing serotonergic psychedelics into an underserved corner of psychiatric medicine — mood and anxiety disorders where current options are either slow to act or poorly tolerated. Its lead asset has already secured FDA Breakthrough Therapy Designation and cleared a Phase 2 trial in postpartum depression, putting Reunion closer to a pivotal study than most in the psychedelic therapeutics space. The company is privately held and headquartered in New Jersey.
Headquarters and Global Presence
Reunion Neuroscience is based in New Jersey, USA. As a privately held clinical-stage company, its operational footprint reflects a focused drug-development model rather than a broad commercial infrastructure.
Founding and History
Reunion traces its origins to Field Trip Health Ltd, a psychedelic health company founded in 2019. In August 2022, Field Trip split into a wellness entity and a dedicated drug-development vehicle that was renamed Reunion Neuroscience Inc. MPM BioImpact acquired Reunion in a $13.1 million deal in June 2023, taking the company private. In May 2024, Reunion closed a $103 million Series A financing co-led by MPM BioImpact and Novo Holdings, one of the largest rounds raised by a psychedelic biotech to date.
Therapy Areas and Focus
Reunion's pipeline is anchored in mood and anxiety disorders where speed of onset and durability of effect are the defining unmet needs. Postpartum depression affects a significant proportion of new mothers and has seen limited pharmacological innovation beyond brexanolone and zuranolone. Adjustment disorder — particularly in patients with cancer or serious medical illness — and generalized anxiety disorder round out a pipeline logic that prioritizes conditions with acute, identifiable triggers. All three indications share a rationale for rapid-acting, single-administration intervention.
Technology Platforms and Modalities
Luvesilocin is a prodrug of 4-OH-DiPT, a serotonergic psychedelic administered subcutaneously. Its defining pharmacokinetic feature is a psychedelic experience of approximately 3 to 4 hours — roughly half the duration of a psilocybin session — which matters practically for clinical administration settings and potentially for patient access and cost. The prodrug design is intended to achieve controlled, predictable exposure via a defined subcutaneous dose. It is the only compound of its chemical class currently in clinical development.
Key Pipeline and Programs
Luvesilocin (RE104) in postpartum depression is the lead program and the most advanced. The RECONNECT Phase 2 trial — a multicenter, randomized, double-blind, active dose-controlled study in 84 patients with moderate-to-severe postpartum depression — demonstrated a statistically significant reduction from baseline of 23.0 points on the MADRS total score at Day 7 following a single 30mg subcutaneous dose, versus 17.2 points in the 1.5mg active control arm (p=0.0094). Improvements appeared as early as Day 1 and were maintained through Day 28. The FDA granted Breakthrough Therapy Designation on February 23, 2026, and following an End of Phase 2 meeting, the agency aligned on a registrational path requiring one successful Phase 3 trial; that pivotal study is planned to initiate in 2026.
The Phase 2 REKINDLE trial (NCT07002034) is evaluating luvesilocin in adjustment disorder related to cancer and other serious medical illnesses — an indication almost entirely absent from the psychedelic drug development pipeline and with essentially no approved pharmacological options.
The Phase 2 RECLAIM trial (NCT07489651) is enrolling patients with generalized anxiety disorder. Reunion expects topline data from RECLAIM in the second quarter of 2027, which would make it a near-term catalyst alongside the PPD pivotal trial initiation.
Recent Developments
On February 23, 2026, the FDA granted Breakthrough Therapy Designation to luvesilocin for postpartum depression — a meaningful regulatory signal that should accelerate development and FDA interaction on the path to Phase 3. On June 15, 2026, Reunion appointed Dr Sahil Kirpekar as President, CEO, and board member, succeeding Greg Mayes; Kirpekar brings direct psychedelic biotech experience from atai Life Sciences and deep CNS business development expertise from over eight years at Otsuka Pharmaceutical. His arrival at this juncture — with a Phase 3 PPD trial to launch and two Phase 2 programs enrolling — positions the company for what will likely be its most consequential 24 months.
Key Personnel
Sahil V. Kirpekar, M.D., serves as President and Chief Executive Officer, appointed June 15, 2026. He is a trained physician with two decades of health sciences experience, previously serving as Chief Business Officer at atai Life Sciences and spending more than eight years at Otsuka Pharmaceutical as Global Head of Business Development, where he led transactions across CNS, immunology, nephrology, rare diseases, and oncology.
Strategic Partnerships
Reunion is backed by a syndicate that includes MPM BioImpact — which acquired the company before leading the Series A — alongside Novo Holdings, Arkin Bio Capital, Mitsui & Co. Global Investment, FemHealth Ventures, Plaisance Capital, and Palo Santo. No external licensing or co-development partnerships have been publicly announced at this stage.
FAQ Section
Breakthrough Therapy Designation for luvesilocin in postpartum depression, granted on February 23, 2026, unlocks intensive FDA guidance during development and can accelerate review timelines. Critically, Reunion has also secured FDA alignment on a registrational path requiring only one successful Phase 3 trial rather than the customary two — a significant de-risking of the development timeline and cost structure. For a privately held company managing a multi-indication expansion, that efficiency has real capital implications.
Luvesilocin is a prodrug of 4-OH-DiPT, a serotonergic psychedelic that acts on the same receptor class as psilocybin but with a markedly shorter pharmacodynamic window — approximately 3 to 4 hours versus 6 to 8 hours for psilocybin-assisted therapy. The subcutaneous route of administration enables controlled dosing and predictable plasma exposure rather than the oral variability seen with psilocybin. This duration profile is not merely academic: shorter sessions reduce the clinical supervision burden per patient and could prove decisive for health system adoption and reimbursement.
Luvesilocin is the only 4-OH-DiPT prodrug in clinical development, giving Reunion a chemically distinct asset rather than a reformulation of psilocybin or MDMA. The subcutaneous administration route, combined with the abbreviated session length, represents a genuinely different clinical product profile. The RECONNECT Phase 2 data — a statistically significant 23.0-point MADRS reduction versus 17.2 in the active control arm — provide human proof-of-concept that sets Reunion apart from many psychedelic programs still operating at preclinical or early Phase 1 stage.
RECONNECT was a multicenter, randomized, double-blind, active dose-controlled study enrolling 84 patients with moderate-to-severe postpartum depression. A single 30mg subcutaneous dose of luvesilocin produced a 23.0-point reduction from baseline in MADRS total score at Day 7, against 17.2 points in the 1.5mg active control arm, a difference that was statistically significant (p=0.0094). The effect appeared as early as Day 1 and persisted through Day 28, suggesting durability from a single administration. The active control design — rather than placebo — strengthens the signal, though the pivotal Phase 3 trial will be the definitive test.
Reunion is deliberately broadening luvesilocin beyond PPD into adjustment disorder related to cancer and serious medical illness (REKINDLE, NCT07002034) and generalized anxiety disorder (RECLAIM, NCT07489651). Adjustment disorder in oncology is a particularly underserved indication with no approved pharmacological treatments, which could reduce competitive friction if the data hold. All three indications share the logic of an acute-onset, single-administration intervention where rapid antidepressant or anxiolytic effect is the primary clinical goal.
Reunion is at the Phase 2-to-Phase 3 inflection point in PPD, its most advanced program, with a pivotal Phase 3 trial planned to initiate in 2026 following FDA alignment on a single-trial registrational path. Two Phase 2 trials are actively enrolling — REKINDLE in adjustment disorder and RECLAIM in generalized anxiety disorder — with RECLAIM data expected in the second quarter of 2027. The appointment of a new CEO in June 2026 with CNS business development expertise signals that partnership or licensing conversations are likely to be a near-term strategic priority.
The key watchpoints over the next 12 to 24 months are:
- Initiation and enrollment progress of the Phase 3 PPD trial, and whether Reunion can secure the capital or partnership to fund it through to readout.
- RECLAIM Phase 2 topline data in generalized anxiety disorder, expected in the second quarter of 2027 — a positive readout would substantially expand the commercial thesis.
- Regulatory progress in a psychedelic therapeutics field that remains subject to evolving DEA scheduling and legislative uncertainty.
- Whether incoming CEO Kirpekar's business development background translates into a licensing or co-development deal with a larger CNS-focused partner.
- Competitive pressure from psilocybin programs and other serotonergic psychedelic assets that are moving toward late-stage development in overlapping indications.
Today's issue
| Headless Content Management with Blaze